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tomographic angiograms analyzed.
CONCLUSIONS Percutaneous transthoracic left atrial access is
feasible in large mammals and in human cadavers under real-time
magnetic resonance or x-ray ﬂuoroscopic guidance. The presence
of potential transthoracic trajectories to the left atrium on
human cardiac computed tomographic analysis suggests clinical
translation is realistic. This technique could provide fully percuta-
neous access to deliver large caliber transcatheter mitral valve
implants.
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BACKGROUND A small number of Transcatheter Mitral Valve Im-
plants (TMVI) have been reported using devices designed to treatsecondary mitral regurgitation (MR). There are a number of technical
challenges for TMVI including device migration, left ventricular
outﬂow tract obstruction (LVOTO) and paravalvular MR. We report 6-
month outcomes of ﬁrst-in-man (FIM) implants with the Tendyne
Bioprosthetic Mitral Valve System.
METHODS Four patients (Table) deemed unsuitable for treatment
with any CE marked device by Heart Team Evaluation underwent
TMVI using a Tendyne system (a tri-leaﬂet porcine pericardial valve
in a tethered self-expanding nitinol frame, with an apical tether
ﬁxed to an epicardial pad to stabilize the device). The device is fully
repositionable and retrievable even after complete deployment.
Device size was chosen based on multidetector computed
tomography (MDCT) tomography to deﬁne mitral annular
dimensions, geometry and guide surgical access. Annular
dimensions were conﬁrmed by intra-operative 3-dimensional
transoesophageal echocardiography. The device was implanted
under TOE-guidance using general anesthesia via a transapical
approach through a small left mini-thoracotomy using a 34Fr sheath
which was advanced over the wire into the left atrium. The device
was advanced into the sheath, extruded, positioned into the correct
anatomical position by rotating the device, and fully deployed. The
apical pad was inserted into position over the tether. The tension on
the tether was then adjusted to optimize the position of the device.
The apical pad facilitated LV apical closure.
RESULTS TMVI procedures were performed between October 2014
and January 2015. All patients had no paravalvular MR, no trans-
valvular MR, and no transmitral gradient immediately after TMVI
(Table). One patient (who had previous mitral annuloplasty)
developed signiﬁcant LVOTO (95mmHg) associated with systolic
anterior motion of the mitral valve. Following LVOT stenting, LVOT
gradient decreased to 47mmHg. All 4 patients were discharged to
their own home, independent of activities of daily living. At 6-
months, all were alive, living independently at home, with no
further heart failure hospital admissions. All showed improvement
in functional capacity and 6-minute walk test. All valves were
stable, with reduction in tricuspid regurgitation and pulmonary
pressures. Two patients had evidence of mild paravalvular
regurgitation and were asymptomatic but with biochemical evidence
of hemolysis.Before TMVI Patient 1 Patient 2 Patient 3 Patient 4Age 68 75 87 75Previous CABG/
MV repairYes Yes No YesPre-TMVI NYHA
ClassIV IV III IIIPre-TMVI EROA
cm2
0.34 0.79 1.39 0.47Pulmonary
Pressure
(mmHg)104 61 75 45LVOT gradient
(mmHg)5 7 6 5Post-TMVI MR
gradeNone Trivial None NoneMean mitral
gradient
(mmHg)3 5 2 5LVOT gradient
(mmHg)8 10 6 47Length of
hospital stay
(days)16 8 8 65Discharge
destinationHome Home Home Home6-month Follow-
Up: AliveYes Yes Yes YesNYHA Class I I I IIDegree of MR on
echoNone Trivial None
B58 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5CONCLUSIONS We report satisfactory 6-month outcomes of ﬁrst-in-
man (FIM) implants with the Tendyne Bioprosthetic Mitral Valve
System. All were living independently at home at 6-months.
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BACKGROUND The ﬁrst-in-class and most widely commercially
available bioresorbable scaffold (BRS) Absorb has strut thickness of
150 microns, far exceeding those of contemporary drug-eluting stents.
As such, it has potential for delivery challenges and higher thrombo-
genicity. As such, decreasing the BRS strut thickness with no adverse
effect on its biomechanics seems desirable. The aim of the study was
to assess safety and efﬁcacy of a novel thin strut (100 mm) sirolimus
eluting BRS (MeRes100, Meril Life Sciences, Gujarat, India) in porcine
coronary arteries.
METHODS A total of 34 coronary segments of 14 healthy swine were
implanted with 24 thin strut sirolimus eluting MeRes100 BRS and 10
Absorb scaffolds at 110% overstretch. To date, angiographic and op-
tical coherence tomography (OCT) imaging were performed after 1 and
3 months (MeRes100 n¼19 and Absorb n¼8 at each time point). Of the
entire cohort, 3 animals were euthanized at each time point and cor-
onary segments were harvested for histological evaluation.
RESULTS The animals in both groups were comparable with regard to
weight, clinical status, baseline vessel size and procedural character-
istics. All procedures were completed with no complications. At the
implantation procedure there was no statistical difference in angio-
graphic, minimal lumen diameter (MLD)-based percent acute recoil
between MeRes100 and Absorb (respectively: 13%  7% vs. 10%  5%
p¼0.18). OCT evaluation demonstrated no differences in metrics of
neointimal proliferation in MeRes100 when compared to Absorb at 1-
and 3-month follow up. Angiographic results corresponded to OCT
and showed similar results without statistical differences in MLD and
late loss at both time points. OCT and angiographic results are sum-
marized in the table. Histological analysis at 1-month follow up
revealed comparable results in MeRes100 and Absorb in % area ste-
nosis (respectively: 28.7  12.6% vs. 27.32.5% p¼0.86), neointimal
area (respectively 1.770.82 vs. 1.950.35 mm2; p¼0.22) and in qual-
itative parameters of vascular healing. Three-month histological re-
sults will be available by the time of the meeting.1 month 3 months
MeRes100 Absorb p MeRes100 Absorb p
A Minimal Lumen
Diameter(mm)
1.980.32 2.200.22 0.07 2.020.32 2.240.26 0.11
Late Loss(mm) 0.610.33 0.590.23 0.85 0.620.30 0.640.18 0.80
T % Area Stenosis 22.48.2 22.67.1 0.96 29.211.6 23.65.3 0.11
Neointimal
Thickness(mm)
0.170.06 0.170.05 0.86 0.220.10 0.180.04 0.86CONCLUSIONS The novel sirolimus-eluting BRS with thinner struts
and hybrid cell design showed similar radial strength and equivalent
inhibition of neointimal proliferation when compared to the bench-
mark Absorb BVS up to 90 days in normal porcine coronary arteries.
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BACKGROUND The J-CTO (Multicenter Chronic Total Occlusion [CTO]
Registry in Japan) score was developed to predict the probability of
successful guidewire crossing within 30 minutes. However, guidewire
crossing alone does not ensure ﬁnal success of CTO PCI. We therefore
sought to develop a novel parsimonious scoring system to estimate
the likelihood of technical success.
METHODS We examined 781 CTO percutaneous coronary in-
terventions (PCI) performed using the “hybrid” approach and
included in the Prospective Global Registry for the Study of Chronic
Total Occlusion Intervention (PROGRESS CTO). To develop the
“PROGRESS CTO” score we analyzed clinical and angiographic pa-
rameters using a derivation and validation cohort (2:1 sampling ratio).
Variables with strong association with technical failure in multivari-
able analysis were assigned 1 point and a 4-point score was developed
from summing all points. The PROGRESS CTO score was subsequently
compared with the J-CTO score in the validation cohort.
RESULTS Technical success was achieved in 726 lesions (92.9%).
Factors associated with technical success on multivariable analysis
included proximal cap ambiguity (beta coefﬁcient b¼0.88), moderate/
severe tortuosity (b¼1.18), left circumﬂex artery CTO PCI (b¼0.99),
and absence of “interventional” collaterals (b¼0.88). The resulting
PROGRESS CTO score demonstrated good calibration and discrimi-
natory capacity in the derivation (Hosmer-Lemeshow c2¼2.633,
p¼0.268 and receiver operator characteristic [ROC] area¼0.778) and
validation subset (Hosmer-Lemeshow c2¼5.333, p¼0.070 and ROC
area¼0.720). In the validation cohort, the PROGRESS CTO and J-CTO
performed similarly in predicting ﬁnal procedural success and
guidewire crossing at 30 minutes, respectively (ROC area 0.720 vs.
0.746, area under the curve AUC difference¼0.026, 95% conﬁdence
interval¼-0.093 to 0.144).
CONCLUSIONS The PROGRESS CTO score is a novel useful tool for
estimating technical success in CTO PCI performed using the hybrid
approach.
